Media stories about Epirus Biopharmaceuticals (NASDAQ:EPRS) have trended positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Epirus Biopharmaceuticals earned a news impact score of 0.27 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.3208758520582 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

COPYRIGHT VIOLATION NOTICE: “Epirus Biopharmaceuticals (EPRS) Receives Daily Media Impact Score of 0.27” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/21/epirus-biopharmaceuticals-eprs-receives-daily-media-impact-score-of-0-27.html.

Epirus Biopharmaceuticals Company Profile

Insider Buying and Selling by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.